Navigation Links
Experimental drug shows encouraging results in treating most common form of lung cancer
Date:11/1/2013

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

Dr. Edward Garon, director of thoracic oncology at UCLA's Jonsson Comprehensive Cancer Center, presented the preliminary results of a Phase 1B study of the new drug, called MK-3475, on Oct. 29 at the World Conference on Lung Cancer in Sydney, Australia.

The detailed interim data on safety and activity came from a cohort of 38 patients with non-small cell lung cancer who were treated previously for the disease without positive results. For the study, the patients received MK-3475 every three weeks.

Among the participants, 24 percent responded to the drug, with their tumors shrinking, and the median overall survival rate was 51 weeks. For those who responded, the median response duration the average amount of time their tumors remained shrunk had not been reached at the time of this analysis, so it is at least 62 weeks.

Based on this data, a Phase 2/3 trial comparing two different doses of MK-3475 to standard chemotherapy for lung cancer has begun enrolling patients.

Some cancer cells can evade detection by the immune system by expressing a protein called PD-L1, which interacts with the protein PD-1 to prevent the immune system from seeing the cancer as an invader. MK-3475, an anti-PD-1 immunotherapy drug made by Merck, allows the immune system to properly detect the cancer and to activate T cells the so-called "foot soldiers" of the immune system to attack and kill cancer cells.

The most commonly reported drug-related side effects in the study were rash (21 percent), skin itching (18 percent), fatigue (16 percent), diarrhea (13 percent) and joint pain (11 percent). Most side effects, however, were of low grade.

"These are early results, but we are very encouraged by what we've seen so far with this drug," Garon said. "Lung cancer patients who have disease that has grown after two prior therapies do not have many options, and we are cautiously optimistic that this might be a treatment that improves their chances in the future."

According to the American Cancer Society, approximately 1.4 million people die from non-small cell lung cancer every year. It is the most common type of lung cancer, representing approximately 85 percent of all lung cancer diagnoses.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
2. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
3. York physicists offer novel insight into experimental cancer treatment
4. Experimental Drug Shows Benefits Against Melanoma in Early Study
5. Experimental Drugs Show Promise Against Prostate Cancer
6. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
7. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
8. Experimental Drug for Hepatitis C Promising, Studies Show
9. Experimental Vaccine Shows Promise for Ovarian Cancer
10. Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
11. Experimental Staph Vaccine Fails to Work, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 07, 2020 , ... As part of their ... during this past spring, The Bengtson Center team decided to temporarily suspend most in-person ... on an individual basis. With the offices now open again, the leading plastic ...
(Date:8/7/2020)... ... August 07, 2020 , ... Mary J's Cannabis ... the assistance of dicentra Cannabis Consulting . , The store, which operates ... It is the first of many locations as the company plans to expand across ...
(Date:8/5/2020)... ... August 05, 2020 , ... AdventHealth Carrollwood has partnered with Bayshore ... class on Monday, August 12, 2020. AdventHealth provided the school with key strategies and ... the classroom setting. , “We are taking extra steps in our hospital and ...
(Date:8/5/2020)... (PRWEB) , ... August 05, 2020 , ... ... announced the appointments of Kathleen Cruger as Director of Clinical Services and Myron ... the company’s growth. , “ChronWell has achieved incredible growth as demand ...
(Date:8/5/2020)... ... August 05, 2020 , ... Today, YPO Africa , a ... and investment platform for Africa, announced that they have entered into a unique bilateral ... Africa to support each other in their African impact efforts, with an initial focus ...
Breaking Medicine News(10 mins):
(Date:8/5/2020)... Va. (PRWEB) , ... August ... ... Cleaning and Disinfectant Programs: , Best Practices During COVID-19, An FDAnews Webinar, ... The task of maintaining a controlled cleanroom is never simple and COVID-19 ...
(Date:8/3/2020)... ... 2020 , ... PMI Advisors, a leading management consulting firm, ... owners. These plans help ensure that companies actually function and survive should ... days as a result of sickness or injury. , A recent survey of ...
(Date:8/3/2020)... ... ... purpose of sleep? Most of us would answer, “to rest” — but how many of ... or tired from a long day at work, or working all day inside our own ... our own daily choices of how we spend our time. Why is that? Dr. ...
Breaking Medicine Technology: